Stockscreener 앱 받기
14.34
7.42%
0.99
시장 영업 전:
14.42
0.08
+0.56%
Tonix Pharmaceuticals Holding Corp 주식(TNXP)의 최신 뉴스
Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development - Sahm
Tonix Pharmaceuticals (TNXP) Reports Positive Findings on TNX-10 - GuruFocus
Tonix publishes pharmacokinetic study on fibromyalgia drug - Investing.com
Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development - GlobeNewswire Inc.
Analyst Upgrade: Can Tonix Pharmaceuticals Holding Corp stock outperform in a bear marketWeekly Earnings Recap & Reliable Price Breakout Alerts - baoquankhu1.vn
TNXP Stock Price, Quote & Chart | TONIX PHARMACEUTICALS HOLDIN (NASDAQ:TNXP) - ChartMill
TNXP Options Volatility — NASDAQ:TNXP - TradingView — Track All Markets
TNXP Options Chain — NASDAQ:TNXP - TradingView — Track All Markets
Profit Recap: Will Tonix Pharmaceuticals Holding Corp announce a stock split2026 Analyst Calls & Daily Chart Pattern Signals - baoquankhu1.vn
Will Tonix Pharmaceuticals Holding Corp stock benefit from M AInflation Watch & Daily Stock Trend Watchlist - baoquankhu1.vn
Why Tonix's External Atty Saw GC Role As A 'Natural Choice' - Law360
Tonix Pharmaceuticals stock hits new 52-week low: What's driving the action? - MSN
Liquidity Mapping Around (TNXP) Price Events - Stock Traders Daily
Tonix Pharmaceuticals Holding Corp at TD Cowen Healthcare Conference Transcript - GuruFocus
Tonix Pharma CEO Lederman buys $63,099 in shares By Investing.com - Investing.com South Africa
Tonix Pharma CEO Lederman buys $63,099 in shares - Investing.com
Tonix (NASDAQ: TNXP) CEO adds 5,000 shares via IRA purchase - Stock Titan
Tonix Pharmaceuticals Holding Corp. (TNXP) stock price, news, quote and history - Yahoo Finance Australia
Tonix plans Phase 2 Lyme disease prevention study in 2027 By Investing.com - Investing.com Australia
Tonix Pharmaceuticals Holding Corp Presents Phase 1 Data And Outlines Planned Adaptive Phase 2 Field Study Of TNX-4800 For Prevention Of Lyme Disease - marketscreener.com
Tonix Pharma Advances TNX-4800 Lyme Disease Prevention Program - TipRanks
Tonix Pharmaceuticals (TNXP) Advances TNX-4800 Lyme Disease Trea - GuruFocus
Tonix plans Phase 2 Lyme disease prevention study in 2027 - Investing.com
Tonix Pharmaceuticals presents Phase 1 TNX-4800 data, aims for adaptive Phase 2 in H1 2027 - TradingView — Track All Markets
Tonix (Nasdaq: TNXP) advances TNX-4800 Lyme prevention antibody on Phase 1 data - Stock Titan
Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026 - GlobeNewswire
Recap Report: Can Tonix Pharmaceuticals Holding Corp stock outperform in a bear marketAnalyst Upgrade & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Tonix Pharmaceuticals Stock Hits New 52-Week Low: What's Driving The Action? - Benzinga
Tonix Pharmaceuticals (NASDAQ: TNXP) puts reverse split and 2026 equity plan to vote - Stock Titan
TNXP Should I Buy - Intellectia AI
TNXP SEC FilingsTonix Pharmaceut 10-K, 10-Q, 8-K Forms - Stock Titan
Tonix Pharmaceuticals (NASDAQ:TNXP) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Vanguard disaggregates holdings after realignment; reports 0 shares in Tonix (TNXP) - Stock Titan
Tonix Pharmaceuticals Holding Corp. Trade Ideas — BOATS:TNXP - TradingView
Tonix doses first patient in migraine treatment study By Investing.com - za.investing.com
Tonix Pharmaceuticals Begins Phase 1 Study of Intranasal Oxytocin (TNX-1900) for Migraine and Craniofacial Pain Treatment - Minichart
Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain - Bitget
Tonix Pharmaceuticals (TNXP) Advances with Phase 1 Study on TNX-1900 - gurufocus.com
Tonix Pharma Begins Phase 1 Study of TNX-1900 - TipRanks
Tonix doses first patient in migraine treatment study - Investing.com
Tonix (NASDAQ: TNXP) doses first subject in TNX-1900 migraine study - Stock Titan
Tonix Pharmaceuticals Holding Corp Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 - marketscreener.com
Q1 Earnings Forecast for TNXP Issued By Zacks Research - MarketBeat
FY2028 Earnings Estimate for TNXP Issued By Zacks Research - Defense World
Why (TNXP) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
FY2028 Earnings Forecast for TNXP Issued By Zacks Research - MarketBeat
2.69%
0.25%
자본화:
|
볼륨(24시간):